Glaxosmithkline Share News (GSK)

Sanofi starts work on $95 mln Algerian plant, biggest in Africa

PARIS, Sept 26 (Reuters) - French drugmaker Sanofi has started construction of a new 70 million-euro ($95 million) plant in Algeria that will be its largest industrial site in Africa, the company said on Thursday. Sanofi, the international drug company with the biggest sales in Africa, alr

INSIGHT-How new cancer drugs can skip randomized trials

By Julie Steenhuysen and Ben Hirschler CHICAGO/LONDON, Sept 26 (Reuters) - In 2006 when doctors started testing a melanoma treatment made by Roche Holding AG on patients, they were used to facing slim odds - about one in eight - that the tumors would shrink on chemotherapy. This time, they

UPDATE 1-U.S. FDA strengthens hepatitis B warning on 2 cancer drugs

WASHINGTON, Sept 25 (Reuters) - U.S. health regulators have strengthened the warnings on two blood cancer drugs to reflect the risk that they may reactivate the hepatitis B virus in patients previously infected with the disease. The warnings affect GlaxoSmithKline Plc's Arzerra, which was

U.S FDA strengthens warnings on Glaxo, Roche/Biogen cancer drugs

Sept 25 (Reuters) - U.S. regulators strengthened the warning labels on two cancer drugs - GlaxoSmithKline Plc's Arzerra, and Rituxan, made by Biogen Idec Inc and Roche Holding AG - to reflect the risk that they can reactivate the hepatitis B virus in patients previously infected with it. T

UPDATE 1-Merck KGaA revives testing of cancer vaccine

* Patients with certain treatment history could benefit * Drug tecemotide formerly known as Stimuvax * Vaccine had failed in previous trial (Adds survival data, background on cancer vaccines) By Ludwig Burger FRANKFURT, Sept 25 (Reuters) - German drugmaker Merck KGaA wi

UK PRESS: GlaxoSmithKline Sales Trouble In China - FT

GSK's China sales may be down 30 pct on bribery scandal -analysts

LONDON, Sept 23 (Reuters) - GlaxoSmithKline's sales in China may have dropped 30 percent since authorities accused it of corruption, disrupting its ability to market medicines in the country, according to analyst estimates. Citigroup said initial feedback following the accusations against G

DIRECTOR DEALINGS: GSK Managers Receive Share-Based Cash Payments

UPDATE 3-Muscular dystrophy drug fails in GSK study, Prosensa slumps

* Drug fails to help patients walk better in Phase III study * Prosensa shares slump 70 percent * Rival Sarepta Therapeutics edges up 2 percent (Adds analyst comments, updates shares) By Ben Hirschler LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular

Four-strain AstraZeneca flu vaccine wins EU green light

LONDON, Sept 20 (Reuters) - A new four-in-one flu vaccine from AstraZeneca has been recommended for approval in Europe, boosting commercial prospects for the next-generation product. Following Friday's green light from the European Medicines Agency, AstraZeneca said it aimed to replace its

MARKET PULSE-Prosensa, Verenium, Cyclacel, Apple, Microsoft

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 20 (Reuters) - Wall Street was set for a slightly lower open on Friday following commen

UPDATE 1-New Roche breast cancer drug wins backing in Europe and Japan

* Kadcyla approved in Japan, recommended for approval in EU * EU agency also backs Algeta/Bayer prostate cancer drug LONDON, Sept 20 (Reuters) - Roche's new breast cancer drug Kadcyla was approved in Japan on Friday and recommended for approval in Europe, building on February's U.S. g

MARKET PULSE-Prosensa, Verenium, Cyclacel, Tibco, NGL, Huntsman

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) Sept 20 (Reuters) - U.S. stock index futures were little changed as investors hoped that rem

MARKET PULSE-Cyclacel, Tibco, NGL, Huntsman

(For more market insights, including options activity, click on ; for the Day Ahead newsletter http://link.reuters.com/mex49s) Sept 20 (Reuters) - Some U.S. stocks to watch on Friday: ** CYCLACEL PHARMACEUTICALS INC, Thursday close $3.80, up 24 pct after market The drugmaker sa

GSK, Prosensa muscular dystrophy drug misses study goal

LONDON, Sept 20 (Reuters) - An experimental drug for Duchenne muscular dystrophy from GlaxoSmithKline and Prosensa failed to meet its goal in a late-stage clinical trial, the companies said on Friday. The drug, drisapersen, did not show a statistically significant improvement in the distanc